A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Trial Profile

A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs F8 IL10 (Primary) ; Methotrexate; Methotrexate; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Philogen
  • Most Recent Events

    • 17 Jun 2017 Results of phase 1b (NCT02076659; n=34) and phase 2 (NCT02270632; Data cut off 22 January 2017; n=22) trials, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 05 Dec 2016 Planned number of patients changed from 34 to 36.
    • 05 Dec 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top